Sumitovant Biopharma Highlights Significant Clinical, Regulatory and Commercial Achievements Across its Portfolio of Companies in the Second Quarter of FY2021

Author's Avatar
Dec 10, 2021

- Enzyvant, a wholly-owned subsidiary of Sumitovant, received FDA approval for RETHYMIC® (allogeneic processed thymus tissue-agdc), a one-time regenerative tissue-based therapy for pediatric congenital athymia

- Myovant, a publicly listed company that is majority-owned by Sumitovant, and its partner Pfizer received FDA acceptance of its supplemental New Drug Application (sNDA) for MYFEMBREE®

- Urovant, a wholly-owned subsidiary of Sumitovant, launched branded co-promotion activities for GEMTESA®

PR Newswire